SAN FRANCISCO – Olema Pharmaceuticals, Inc. (NASDAQ: OLMA ) Director Cyrus Harmon sold a total of 25,000 shares of the company’s stock in a series of transactions valued at approximately $257,450. The sale was made pursuant to a prearranged 10b5-1 trading plan, which is a vehicle for company insiders to sell stock in a predetermined manner.
The transactions occurred between May 31 and June 4, with Harmon selling shares at prices between $9.41 and $12.33. On May 31, Harmon sold 15,000 shares at an average price of $9.41, followed by 5,000 shares on June 3 at an average price of $10.93, and on June 4 at an average price of $12.33. Sold another 5,000 shares.
Following the completion of these transactions, Harmon still holds a significant stake in Olema Pharmaceuticals. Investors may submit a request to the SEC, the issuer, or any of the issuer’s security holders to obtain details regarding the exact number of shares sold at each price point.
Olema Pharmaceuticals is a biopharmaceutical company focused on discovering and developing targeted therapies for women’s cancer. Recent transactions by a company’s directors may be of interest to current and potential investors, providing an insight into the company’s inner activities.
The shares are held indirectly by Harmon through Harmon Family Investors LLC, of which Harmon serves as manager, highlighting the importance of understanding the nature of ownership when evaluating insider transactions.
The sale was executed in compliance with all applicable securities laws, and the remaining shares owned by Cyrus Harmon following the transaction underscore his continued investment in the company’s future.
Investment Professional Insights
Given the recent insider trading activity at Olema Pharmaceuticals, Inc. (NASDAQ: OLMA ), investors may be seeking more context to better understand the company’s financial health and market performance. InvestingPro data shows that the company’s market capitalization is US$780.27 million, which shows the company’s size and scale in the biopharmaceutical field. Notably, the company’s price-to-earnings ratio is -6.81, reflecting market expectations for future profit growth, even though it’s not yet profitable.
Aside from its financials, Olema Pharmaceuticals’ share price has also seen significant movement, with a 1-year total price return of 135.13%, showing strong returns over the past year. The 1-week total price return is 44.97%, which may be consistent with recent insider transactions by director Cyrus Harmon.
InvestingPro Tips suggests that Olema Pharmaceuticals has more cash than debt on its balance sheet, which could be a reassuring sign for investors considering the company’s financial resilience. Additionally, 3 analysts have upgraded earnings for the period ahead, which could indicate a positive outlook for the company’s future performance. For investors interested in a more in-depth analysis, there are over 10 additional InvestingPro Tips providing insights such as Olema Pharmaceuticals’ gross margin and net profit expectations. These can be further explored by visiting the InvestingPro platform.
For those wishing to take advantage of this information, please use the exclusive coupon code PRONEWS24 Subscribe to InvestingPro’s Pro and Pro+ annually or every two years to get an additional 10% discount, thereby gaining access to rich data and analysis to inform investment decisions.
This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.
